M Calayag-Jung

Suggest Changes
Learn More
PURPOSE We conducted a phase I trial of the novel nucleoside analog, gemcitabine, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) to determine the maximum-tolerated(More)
  • 1